drugset / Trial / NCT05077384
Open-label Study of Surufatinib in Japanese Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.
Timeline
- Start
- 2021-09-02
- Primary completion
- 2024-09-06
- Completion
- 2025-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |